Sanofi SA (SNY) Q4 2019 earnings call dated Feb. 06, 2020 Corporate Participants: Felix Lauscher -- Head of Investor Relations Paul Hudson -- Chief Executive Officer
Sanofi SA (NASDAQ: SNY) Q4 2019 Earnings Call Transcript
Categories
Biotechnology
Quest Diagnostics Inc. (NYSE: DGX) Q4 2019 Earnings Call Transcript
Quest Diagnostics (DGX) Q4 2019 earnings call dated Jan. 30, 2020 Corporate Participants: Shawn Bevec -- Vice President of Investor Relations Stephen H. Rusckowski -- Chairman,
Vertex Pharmaceuticals (VRTX) stock soars to record high on bullish outlook
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) continues to be in the luxury of escaping from the COVID-19 pandemic crisis. The stock reflected the
Illumina Inc (NASDAQ: ILMN) Q4 2019 Earnings Call Transcript
Illumina Inc (NASDAQ: ILMN) Q4 2019 Earnings Conference Call January 29, 2020 Corporate Participants: Jacquie Ross -- Investor Relations Francis deSouza -- President and Chief Executive Officer
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Call Transcript
AbbVie Inc (NYSE: ABBV) Q4 2019 Earnings Conference Call February 07, 2020 Corporate Participants: Liz Shea -- Vice President of Investor Relations Richard A. Gonzalez -- Chairman
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Call Transcript
Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Conference Call February 26, 2020 Corporate Participants: Stephanie C. Diaz -- President and Chief Executive Officer Brian
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
Companies that are working on the coronavirus vaccine
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone.
Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19
Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The
Ocugen (OCGN) posts narrower-than-expected loss in FY19
Ocugen, Inc. (NASDAQ: OCGN) reported a wider loss in fiscal 2019 due to expenses related to the change in fair value of
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Call Transcript
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz -- Senior Director of Investor Relations John
Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot
-- Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. -- Net loss
Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects
Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer
Why investors need to take note as Veru Inc transforms into a prostate cancer firm
According to the American Cancer Society, prostate cancer is the second most common form of cancer among men in the US, affecting almost
Three biotech stocks popped up today on Covid-19 treatment related announcements
Biotech companies all over the world have been trying to find the treatment and vaccine for the coronavirus pandemic since January of
Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected. -- Total revenue
CorMedix (NYSE: CRMD): Q4 2019 Earnings Snapshot
-- CorMedix Inc. (NYSE: CRMD) reported a fourth-quarter 2019 loss of $0.21 per share versus a loss of $0.24 per share expected.
Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot
-- Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss
Fresh hope for Covid-19 patients as AbbVie (ABBV) leads studies on HIV drug
For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was declared a
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
-- Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter
Novavax (NVAX) posts wider-than-expected loss in Q4
Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower expenses. The